{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:21:45Z","timestamp":1795022505885,"version":"4.10.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"he 2021 Putian University In-School Research Project","award":["2021062"],"award-info":[{"award-number":["2021062"]}],"id":[{"id":"https:\/\/ror.org\/00jmsxk74","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:p>\n                    We assessed the effects of a new quadruple anti-heart failure treatment on the blood pressure rhythm of patients with acute heart failure and its relationship with heart failure prognosis. A total of 135 patients with heart failure were treated with the new quadruple anti-heart failure treatment. Dynamic blood pressure was monitored before and after treatment for 12 to 16 weeks, and changes in the blood pressure rhythm were analyzed. The Kaplan\u2013Meier method was used to calculate the 1-year incidence of major adverse cardiovascular events (MACE). Before and after 12 to 16 weeks of the new quadruple anti-heart failure treatment, the respective mean blood pressure drop rates were 0.44%\u2005\u00b1\u20050.086 and 4.42%\u2005\u00b1\u20050.068 (t\u2005=\u2005\u22126.149,\n                    <jats:italic toggle=\"yes\">P\u2005&lt;\u2005<\/jats:italic>\n                    .001); the systolic blood pressure (SBP) drop rates were 0.54%\u2005\u00b1\u20050.089 and 5.59%\u2005\u00b1\u20050.069 (t\u2005=\u2005\u22127.534,\n                    <jats:italic toggle=\"yes\">P\u2005&lt;\u2005<\/jats:italic>\n                    .001); and the diastolic blood pressure (DBP) drop rates were 0.25%\u2005\u00b1\u20050.104 and 3.37%\u2005\u00b1\u20050.08 (t\u2005=\u2005\u22123.943,\n                    <jats:italic toggle=\"yes\">P\u2005&lt;\u2005<\/jats:italic>\n                    .001); while the mean blood pressure dipper type ratios were 13.3% and 25.9% (\u03c7\u00b2\u2005=\u200529.077,\n                    <jats:italic toggle=\"yes\">P\u2005&lt;\u2005<\/jats:italic>\n                    .001); the systolic dipper type ratios were 13.3% and 28.1% (\u03c7\u00b2\u2005=\u20057.714,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005); and the diastolic dipper type ratios were 12.6% and 23.0% (\u03c7\u00b2\u2005=\u200514.139,\n                    <jats:italic toggle=\"yes\">P\u2005&lt;\u2005<\/jats:italic>\n                    .001). The 1-year MACE incidence rate in the posttreatment dipper-type blood pressure group was lower than that in the non-dipper-type group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), and the 1-year MACE incidence rate in patients with improvement in blood pressure rhythm after treatment was lower than that in the non-improvement group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). The blood pressure rhythms before and after treatment were finally divided into 4 subgroups; 1-year MACE incidence in the mean blood pressure rhythm (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.037), SBP rhythm (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008), and DBP rhythm (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005) was the lowest in the dipper-type dipper type group. The new quadruple anti-heart failure treatment regimen can improve the blood pressure rhythm in patients with acute heart failure, and this improvement was associated with a decreased MACE incidence in these patients within 1 year.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045107","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:54Z","timestamp":1761332514000},"page":"e45107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Changes in blood pressure rhythm after new quadruple anti-heart failure treatment and its impact on heart failure prognosis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6192-8674","authenticated-orcid":false,"given":"Binxiong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Putian First Hospital, Putian, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Putian First Hospital, Putian, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshuang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Physical Examination, Putian First Hospital, Putian, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","first-page":"760","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2018.","volume":"46","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"e008052","DOI":"10.1161\/CIRCHEARTFAILURE.120.008052","article-title":"Cardiac and noncardiac disease burden and treatment effect of sacubitril\/valsartan: insights from a combined PARAGON-HF and PARADIGM-HF analysis.","volume":"14","author":"Rohde","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"277","DOI":"10.26599\/1671-5411.2025.03.002","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2024.","volume":"22","author":"Zhang","year":"2025","journal-title":"J Geriatr Cardiol"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R8-20261118","first-page":"186","article-title":"Prognostic value of blood pressure rhythmicity for estimated glomerular filtration rate in male hypertensive patients aged 55 and older.","volume":"11","author":"Wang","year":"2025","journal-title":"Kidney Dis (Basel)"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/01658107.2025.2505616","article-title":"24-Hour blood pressure patterns in NAION: exploring the impact of dipping classifications and comorbidities.","volume":"49","author":"\u00d6zdemir","year":"2025","journal-title":"Neuroophthalmology"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1253\/circj.CJ-16-0740","article-title":"Riser pattern is a novel predictor of adverse events in heart failure patients with preserved ejection fraction.","volume":"81","author":"Komori","year":"2017","journal-title":"Circ J"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41440-023-01368-x","article-title":"Nocturnal systolic blood pressure dipping and progression of chronic kidney disease.","volume":"47","author":"Park","year":"2024","journal-title":"Hypertens Res"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/hr.2016.166","article-title":"Circadian rhythm of blood pressure and the renin-angiotensin system in the kidney.","volume":"40","author":"Ohashi","year":"2017","journal-title":"Hypertens Res"},{"key":"R13-20261118","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.111.179119","article-title":"Aging, blood pressure, and heart failure: what are the connections.","volume":"58","author":"Franklin","year":"2011","journal-title":"Hypertension"},{"key":"R14-20261118","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/07420528.2021.1939367","article-title":"Elevated asleep blood pressure and non-dipper 24h patterning best predict risk for heart failure that can be averted by bedtime hypertension chronotherapy: A review of the published literature.","volume":"40","author":"Hermida","year":"2023","journal-title":"Chronobiol Int"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","article-title":"The mechanism of action of LCZ696.","volume":"2","author":"Menendez","year":"2016","journal-title":"Card Fail Rev"},{"key":"R16-20261118","doi-asserted-by":"crossref","first-page":"e036689","DOI":"10.1161\/JAHA.124.036689","article-title":"Phosphodiesterase 9 Inhibition combined with valsartan and with sacubitril\/valsartan in experimental ovine heart failure.","volume":"13","author":"Scott","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R17-20261118","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R18-20261118","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy.","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"R19-20261118","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CRD.0000000000000501","article-title":"Sodium-glucose co-transporter 2 inhibitors in patients with heart failure with preserved ejection fraction: proposed mechanisms, recent evidence, and clinical implications.","volume":"32","author":"Plosker","year":"2024","journal-title":"Cardiol Rev"},{"key":"R20-20261118","doi-asserted-by":"crossref","first-page":"e027612","DOI":"10.1161\/JAHA.122.027612","article-title":"Twenty-four-hour blood pressure-lowering efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double-blind multicenter study.","volume":"12","author":"Kario","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R21-20261118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R22-20261118","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","article-title":"Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction.","volume":"83","author":"Patel","year":"2023","journal-title":"Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:01:06Z","timestamp":1795021266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":22,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045107","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}